5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes

Hsueh Yun Lee; Sheng Jun Fan; Fang I. Huang; Hsin Yi Chao; Kai Cheng Hsu; Tony Eight Lin; Teng Kuang Yeh; Mei Jung Lai; Yu Hsuan Li; Hsiang Ling Huang; Chia Ron Yang; Jing Ping Liou

doi:10.1021/acs.jmedchem.8b00151

5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes

Hsueh Yun Lee, Sheng Jun Fan, Fang I. Huang, Hsin Yi Chao, Kai Cheng Hsu, Tony Eight Lin, Teng Kuang Yeh, Mei Jung Lai, Yu Hsuan Li, Hsiang Ling Huang, Chia Ron Yang, Jing Ping Liou

Research output: Contribution to journal › Article › peer-review

40 Citations (Scopus)

Abstract

This paper reports the development of a series of 5-aroylindolyl-substituted hydroxamic acids. N-Hydroxy-4-((5-(4-methoxybenzoyl)-1H-indol-1-yl)methyl)benzamide (6) has potent inhibitory selectivity against histone deacetylase 6 (HDAC6) with an IC ₅₀ value of 3.92 nM. It decreases not only the level of phosphorylation of tau proteins but also the aggregation of tau proteins. Compound 6 also shows neuroprotective activity by triggering ubiquitination. In animal models, compound 6 is able to ameliorate the impaired learning and memory, and it crosses the blood-brain barrier after oral administration. Compound 6 can be developed as a potential treatment for Alzheimer's disease in the future.

Original language	English
Pages (from-to)	7087-7102
Number of pages	16
Journal	Journal of Medicinal Chemistry
Volume	61
Issue number	16
DOIs	https://doi.org/10.1021/acs.jmedchem.8b00151
Publication status	Published - Aug 23 2018

ASJC Scopus subject areas

Molecular Medicine
Drug Discovery

Access to Document

10.1021/acs.jmedchem.8b00151

Cite this

@article{ba6c7d44d2134168bd623718d62b2514,

title = "5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes",

abstract = "This paper reports the development of a series of 5-aroylindolyl-substituted hydroxamic acids. N-Hydroxy-4-((5-(4-methoxybenzoyl)-1H-indol-1-yl)methyl)benzamide (6) has potent inhibitory selectivity against histone deacetylase 6 (HDAC6) with an IC 50 value of 3.92 nM. It decreases not only the level of phosphorylation of tau proteins but also the aggregation of tau proteins. Compound 6 also shows neuroprotective activity by triggering ubiquitination. In animal models, compound 6 is able to ameliorate the impaired learning and memory, and it crosses the blood-brain barrier after oral administration. Compound 6 can be developed as a potential treatment for Alzheimer's disease in the future. ",

author = "Lee, {Hsueh Yun} and Fan, {Sheng Jun} and Huang, {Fang I.} and Chao, {Hsin Yi} and Hsu, {Kai Cheng} and Lin, {Tony Eight} and Yeh, {Teng Kuang} and Lai, {Mei Jung} and Li, {Yu Hsuan} and Huang, {Hsiang Ling} and Yang, {Chia Ron} and Liou, {Jing Ping}",

year = "2018",

month = aug,

day = "23",

doi = "10.1021/acs.jmedchem.8b00151",

language = "English",

volume = "61",

pages = "7087--7102",

journal = "Journal of Medicinal Chemistry",

issn = "0022-2623",

publisher = "American Chemical Society",

number = "16",

}

TY - JOUR

T1 - 5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes

AU - Lee, Hsueh Yun

AU - Fan, Sheng Jun

AU - Huang, Fang I.

AU - Chao, Hsin Yi

AU - Hsu, Kai Cheng

AU - Lin, Tony Eight

AU - Yeh, Teng Kuang

AU - Lai, Mei Jung

AU - Li, Yu Hsuan

AU - Huang, Hsiang Ling

AU - Yang, Chia Ron

AU - Liou, Jing Ping

PY - 2018/8/23

Y1 - 2018/8/23

N2 - This paper reports the development of a series of 5-aroylindolyl-substituted hydroxamic acids. N-Hydroxy-4-((5-(4-methoxybenzoyl)-1H-indol-1-yl)methyl)benzamide (6) has potent inhibitory selectivity against histone deacetylase 6 (HDAC6) with an IC 50 value of 3.92 nM. It decreases not only the level of phosphorylation of tau proteins but also the aggregation of tau proteins. Compound 6 also shows neuroprotective activity by triggering ubiquitination. In animal models, compound 6 is able to ameliorate the impaired learning and memory, and it crosses the blood-brain barrier after oral administration. Compound 6 can be developed as a potential treatment for Alzheimer's disease in the future.

AB - This paper reports the development of a series of 5-aroylindolyl-substituted hydroxamic acids. N-Hydroxy-4-((5-(4-methoxybenzoyl)-1H-indol-1-yl)methyl)benzamide (6) has potent inhibitory selectivity against histone deacetylase 6 (HDAC6) with an IC 50 value of 3.92 nM. It decreases not only the level of phosphorylation of tau proteins but also the aggregation of tau proteins. Compound 6 also shows neuroprotective activity by triggering ubiquitination. In animal models, compound 6 is able to ameliorate the impaired learning and memory, and it crosses the blood-brain barrier after oral administration. Compound 6 can be developed as a potential treatment for Alzheimer's disease in the future.

UR - http://www.scopus.com/inward/record.url?scp=85050635071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050635071&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.8b00151

DO - 10.1021/acs.jmedchem.8b00151

M3 - Article

AN - SCOPUS:85050635071

VL - 61

SP - 7087

EP - 7102

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 16

ER -

5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this